TGFβ1, TGFβ2, and TGFβ3 Protein Expression in Gastric Carcinomas: Correlation with Prognostics Factors and Patient Survival

Journal of Surgical Research

Volumn 139, Issue 2, 2007, Pages 182-188

  Vagenas, Konstantinos ^a   Spyropoulos, Charalambos ^a   Gavala, Vasiliki ^a   Tsamandas, Athanassios C ^a  

^a UNIVERSITY OF PATRAS   (Greece)

Author keywords

gastric carcinoma; prognostic factors; transforming growth factor

Indexed keywords

BIOTIN; PARAFFIN; STREPTAVIDIN; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA1 ANTIBODY; TRANSFORMING GROWTH FACTOR BETA2; TRANSFORMING GROWTH FACTOR BETA2 ANTIBODY; TRANSFORMING GROWTH FACTOR BETA3; TRANSFORMING GROWTH FACTOR BETA3 ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; EPITHELIUM CELL; FEMALE; GASTRECTOMY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MORPHOLOGY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; STOMACH CARCINOMA; STOMACH MUCOSA; ADENOCARCINOMA; DISEASE COURSE; METABOLISM; MIDDLE AGED; PATHOLOGY; STOMACH TUMOR; SURVIVAL;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; FEMALE; GASTRECTOMY; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TRANSFORMING GROWTH FACTOR BETA3;

EID: 34047262040     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2006.10.005     Document Type: Article

References (26)

1. Rosai J. Stomach. In: Rosai J. (Ed). Rosai and Ackerman's Surgical Pathology (2004), Mosby, New York 648
2. Swan R., and Miner T.J. Current role of surgical therapy in gastric cancer. World J Gastroenterol 12 (2006) 372
3. Kodera Y., Fujiwara M., Koike M., et al. Chemotherapy as a component of multimodal therapy for gastric carcinoma. World J Gastroenterol 12 (2006) 2000
4. Ohtsu A., Yoshida S., and Saijo N. Disparities in gastric cancer chemotherapy between the East and West. J Clin Oncol 24 (2006) 2188
5. Massague J. TGF-β signal transduction. Annu Rev Biochem 67 (1998) 753
6. Grau A.M., Zhang L., Wang W., et al. Induction of p21waf1 expression and growth inhibition by transforming growth factor β involves the tumor suppressor gene DPC4 in human pancreatic adenocarcinoma cells. Cancer Res 57 (1997) 3929
7. Hannon G.J., and Beach D. p15INK4B is a potential effector of TGF-β-induced cell cycle arrest. Nature 371 (1994) 257
8. Reynisdottir I., Polyak K., Iavarone A., et al. Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-β. Genes Dev 9 (1995) 1831
9. Sandhu C., Garbe J., Bhattacharya N., et al. Transforming growth factor β stabilizes p15INK4B protein, increases p15INK4B-cdk4 complexes, and inhibits cyclin D1-cdk4 association in human mammary epithelial cells. Mol Cell Biol 17 (1997) 2458
10. Toyoshima H., and Hunter T. p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell 78 (1994) 67
11. Akiyama Y., Iwanaga R., Saitoh K., et al. Transforming growth factor β type II receptor gene mutations in adenomas from hereditary nonpolyposis colorectal cancer. Gastroenterology 112 (1997) 33
12. Togo G., Toda N., Kanai F., et al. A transforming growth factor β type II receptor gene mutation common in sporadic cecum cancer with microsatellite instability. Cancer Res 56 (1996) 5620
13. Sanford L.P., Ormsby I., Gittenberger-de Groot A.C., et al. TGFβ2 knockout mice have multiple developmental defects that are nonoverlapping with other TGFβ knockout phenotypes. Development 124 (1997) 2659
14. Friedman E., Gold L.I., Klimstra D., et al. High levels of transforming growth factor β 1 correlate with disease progression in human colon cancer. Cancer Epidemiol Biomarkers Prev 4 (1995) 549
15. Kucharzik T., Lugering N., Winde G., et al. Colon carcinoma cell lines stimulate monocytes and lamina propria mononuclear cells to produce IL-10. Clin Exp Immunol 110 (1997) 296
16. Tsamandas A.C., Zolota V., Batistatou A., et al. The potential role of TGFβ1, p21, and Ki67 expression in colorectal carcinomas. Hepatogastroenterology 48 Suppl 1 (2001) CLI
17. Park II D., Son H.J., Song S.Y., et al. Role of TGF-β 1 and TGF-β type II receptor in gastric cancer. Korean J Intern Med 17 (2002) 160
18. Kuwahara A., Katano M., Nakamura M., et al. New therapeutic strategy for gastric carcinoma: A two-step evaluation of malignant potential from its molecular biologic and pathologic characteristics. J Surg Oncol 72 (1999) 142
19. Saito H., Tsujitani S., Oka S., et al. The expression of transforming growth factor-β1 is significantly correlated with the expression of vascular endothelial growth factor and poor prognosis of patients with advanced gastric carcinoma. Cancer 15 (1999) 86:-1455
20. Nakamura M., Katano M., Kuwahara A., et al. Transforming growth factor β1 (TGF-β1) is a preoperative prognostic indicator in advanced gastric carcinoma. Br J Cancer 78 (1998) 1373
21. Nakamura M., Katano M., Fujimoto K., et al. A new prognostic strategy for gastric carcinoma: mRNA expression of tumor growth-related factors in endoscopic biopsy specimens. Ann Surg 226 (1997) 35
22. Stomach. In: Greene F.L., Page D.L., Fleming I.D., et al. (Eds). AJCC Cancer Staging Handbook, TNM Classification of malignant tumors (2002), Springer, New York 111
23. Jass J.R., and Sobin L.H. Histological typing of intestinal tumors: World Health Organization. 2nd ed (1989), Springer, New York
24. Scopa C.D., Vagianos C., Kardamakis D., et al. bcl-2/bax ratio as a predictive marker for therapeutic response to radiotherapy in patients with rectal cancer. Appl Immunohistochem Mol Morphol 9 (2001) 329
25. Shull M.M., Ormsby I., Kier A.B., et al. Targeted disruption of the mouse transforming growth factor-β 1 gene results in multifocal inflammatory disease. Nature 359 (1992) 693
26. Proetzel G., Pawlowski S.A., Wiles M.V., et al. Transforming growth factor-β 3 is required for secondary palate fusion. Nat Genet 11 (1995) 409